MCH ADVISORY RESEARCH
Health Care

Pharmaceuticals

9 companies under coverage.

Coverage

Pharmaceuticals


Equity Research

Zoetis Inc (ZTS)

HOLD. 12-month probability-weighted target $75 (-3% vs spot). P/E Multiple explains 79% of Monte Carlo outcome variance.

ZTSEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Viatris Inc (VTRS)

BUY. 12-month probability-weighted target $20 (+21% vs spot). P/E Multiple explains 65% of Monte Carlo outcome variance.

VTRSEquity ResearchMonte Carlo
25 August 2026Rating: BUY
Equity Research

Pfizer Inc (PFE)

SELL. 12-month probability-weighted target $23 (-17% vs spot). P/E Multiple explains 75% of Monte Carlo outcome variance.

PFEEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Merck & Company Inc (MRK)

SELL. 12-month probability-weighted target $122 (-19% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.

MRKEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Eli Lilly and Company (LLY)

SELL. 12-month probability-weighted target $1100 (-12% vs spot). P/E Multiple explains 86% of Monte Carlo outcome variance.

LLYEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Johnson & Johnson (JNJ)

SELL. 12-month probability-weighted target $240 (-12% vs spot). P/E Multiple explains 78% of Monte Carlo outcome variance.

JNJEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Jazz Pharmaceuticals PLC (JAZZ)

HOLD. 12-month probability-weighted target $252 (-1% vs spot). P/E Multiple explains 89% of Monte Carlo outcome variance.

JAZZEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Elanco Animal Health (ELAN)

HOLD. 12-month probability-weighted target $25 (+1% vs spot). Gross Margin explains 55% of Monte Carlo outcome variance.

ELANEquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Bristol-Myers Squibb Company (BMY)

SELL. 12-month probability-weighted target $57 (-16% vs spot). P/E Multiple explains 76% of Monte Carlo outcome variance.

BMYEquity ResearchMonte Carlo
25 August 2026Rating: SELL
MCH ADVISORY SERVICES · All research · Not investment advicemchadvisoryservices.com ↗ · Research Standard v4 (decision-level) · Research OS ros-1.19.0 · US-listed · UK English